BioSpace News Archive

- Treatment with TTP399 resulted in significant improvements in HbA1c with reduction in insulin, without increasing risk of hypoglycemia or diabetic ketoacidosis (DKA) -

- Real-world data(1) presented at the American Diabetes Association 80th Scientific Sessions suggest people with type 2 diabetes can achieve similar outcomes to adding insulin therapy for both long-acting insulin or non-insulin users - A separate late-breaking trial(2) demonstrates FreeStyle Libre portfolio use is associated with significant reductions of acute diabetes events and hospitalizations for a similar population [13-

Eli Lilly and Company commits 25,000 employee volunteer hours of service to help speed progress

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today presented positive real-world data from early use of the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed loop technology, demonstrating statistically significant improvements in sensor Time in Range (70-180 mg/dL) in people living with both type 1 and type 2 diabetes with no increase in hypoglycemia (<

T1D Exchange to Present Ten Studies Focused on Quality Improvement, Population Health and Real-World Evidence in Type 1 Diabetes at 80 th American Diabetes Association Scientific Sessions Two Studies Selected by Close Concerns as Top 50 Most Notable Posters Among 2,000+ Posters BOSTON--( BUSINESS WIRE )-- T1D Exchange today announced that it will share data from ten abstracts, including six late breaking, focused on quality improvement, populatio

Additional real-world evidence presented at ADA and published in Clinical Diabetes shows participation in Onduo virtual care program reduces diabetes-related distress in participants with elevated baseline distress Onduo to host webinar on Monday, July 6th at 2 pm ET to discuss future of virtual care and CGMs BOSTON--( BUSINESS WIRE )-- This week Onduo presented research results at the American Diabetes Association’s (ADA) 80th Scientific Ses

New real-world data showed Trulicity ® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or exenatide (BCise pen) in people with type 2 diabetes new to GLP-1 receptor agonist (RA) treatment. 1 Eli Lilly and Company (NYSE: LLY) presented these data today during the Amer

MannKind Corporation announced that data from a new clinical study of Afrezza® Inhalation Powder will be presented at the American Diabetes Association’s 80th Scientific Sessions during the ePoster session on Saturday, June 13, 2020.

In lieu of a daily in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Post-hoc closed testing analysis suggests onset of a migraine preventive effect with intravenous VYEPTI as early as day 1 following the initial dose